KHB(SZ:002022)2023-04-25 13:10Company Overview - Shanghai Kehua Bio-engineering Co., Ltd. was established in 1981 and is the first company listed on the Shenzhen Stock Exchange's SME board in the IVD sector [2] - The company specializes in in vitro diagnostics (IVD) and has the most comprehensive product line in the industry [2] Financial Performance - In 2022, the company's operating revenue reached CNY 6.97 billion, representing a year-on-year growth of 43.58% [2] - The net profit attributable to shareholders was CNY 971 million, with a year-on-year increase of 14.16% [2] Product and Market Reach - The company develops, produces, and sells IVD reagents and medical testing instruments, covering molecular diagnostics, biochemical diagnostics, immunodiagnostics, and rapid testing [2] - Kehua's products are distributed across over 30 provinces and municipalities in China, reaching more than 12,000 hospitals, 500 disease control centers, blood centers, blood stations, biopharmaceutical companies, and research institutions, and are exported to over 100 countries and regions [3] Strategic Initiatives - The company aims to achieve full industry chain coverage in the IVD field, providing diversified services to customers [3] - Kehua is expanding its third-party medical testing business and increasing its R&D investment [3] Competitive Position - The company maintains a competitive advantage with a rich product line of over 100 reagents and instruments in molecular diagnostics, biochemical diagnostics, and immunodiagnostics [3] - While international giants like Roche, Abbott, Siemens, and Beckman have strong competitiveness, the trend of domestic substitution is emerging, and the gap between domestic and foreign companies is narrowing [3] Shareholder Developments - Gree Real Estate's wholly-owned subsidiary, Zhuhai Baolian, has become the largest shareholder, which is seen as a significant step towards expanding into the biopharmaceutical and healthcare sectors [3] Corporate Governance - The company decided to terminate the major asset restructuring involving the acquisition of the remaining 38% equity of Tianlong Company after careful consideration and consensus with minority shareholders [4] - The company will not adjust the conversion price of its convertible bonds, maintaining confidence in its long-term stable development [4] - Future stock incentive plans will be considered to attract and retain talent, with strict adherence to regulatory disclosure obligations [4]